238 related articles for article (PubMed ID: 33469292)
1. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
2. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
3. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
Choi YS; Hoory T; Monie A; Wu A; Connolly D; Hung CF
Vaccine; 2008 Oct; 26(46):5855-63. PubMed ID: 18771701
[TBL] [Abstract][Full Text] [Related]
4. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
5. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
6. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.
Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
9. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
Glaffig M; Stergiou N; Schmitt E; Kunz H
ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
[TBL] [Abstract][Full Text] [Related]
11. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
12. Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.
Choi Y; Jeon YH; Jang JY; Chung JK; Kim CW
Mol Ther; 2011 May; 19(5):979-89. PubMed ID: 21063392
[TBL] [Abstract][Full Text] [Related]
13. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
14. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
15. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
16. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
Ryan SO; Turner MS; Gariépy J; Finn OJ
Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
[TBL] [Abstract][Full Text] [Related]
18. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
[TBL] [Abstract][Full Text] [Related]
19. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
[TBL] [Abstract][Full Text] [Related]
20. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.
Zhou SH; Li YT; Zhang RY; Liu YL; You ZW; Bian MM; Wen Y; Wang J; Du JJ; Guo J
Front Immunol; 2022; 13():857779. PubMed ID: 35371101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]